New drug combo shows promise for advanced liver cancer
NCT ID NCT06519721
First seen Apr 25, 2026 · Last updated May 09, 2026 · Updated 3 times
Summary
This study tests whether adding an experimental drug (VIC-1911) to a standard targeted therapy (lenvatinib) can safely shrink tumors and slow disease progression in people with advanced liver cancer. About 12 adults aged 18-75 with stage C liver cancer and good liver function will receive the combination. The goal is to see if the treatment helps control the cancer, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.